Author: HARMEHAR SINGH
Abstract—The integration of artificial intelligence into scientific research has generated widespread optimism regarding accelerated discovery timelines in drug development, protein modeling, and materials science. However, a significant gap remains between computational hit generation and empirical validation. This paper evaluates the capabilities and limitations of machine learning in physical sciences. By analyzing clinical trial attrition rates, chemical space constraints, and structural prediction boundaries, we demonstrate that while machine learning significantly improves screening efficiency, it functions primarily as an instrument of scientific augmentation rather than an autonomous discovery paradigm.
I. Introduction
Scientific progress has historically relied on an iterative cycle of hypothesis formulation, empirical experimentation, and observational refinement. In recent years, deep learning architectures have been integrated into this workflow to navigate complex, multi-dimensional search spaces (Wang et al., 2023). While these computational frameworks excel at pattern matching and structural interpolation, a fundamental question persists: do machines genuinely accelerate functional scientific breakthroughs, or do they primarily streamline early-stage candidate generation?
Unlike closed-system environments governed by explicit rules, such as chess or Go, biological and material systems are open, dynamic, and probabilistic (Hasselgren & Oprea, 2023). This paper examines the real-world performance of artificial intelligence across medicinal chemistry, protein folding, and materials synthesis, highlighting why physical reality continues to impose strict constraints on computational speed.
II. Drug Discovery and Protein Modeling
In drug discovery, generative models and large language models have driven significant early-stage pipeline expansion, with over 170 active computational programs entering clinical evaluation. Nevertheless, empirical tracking reveals that no end-to-end AI-discovered drug has achieved full regulatory approval (Hasselgren & Oprea, 2023). While computational models optimize early ADMET properties—yielding high Phase I success rates between 80% and 90%—late-stage Phase II efficacy success drops sharply to approximately 40%, reflecting the unyielding complexity of human disease biology (Jayatunga et al., 2024). Furthermore, models trained on biomedical literature face severe hurdles due to low baseline reproducibility rates in published assays (Bayer at 33%, Amgen at 11%) and widespread data leakage across benchmark datasets (Hasselgren & Oprea, 2023; Kapoor & Narayanan, 2023).
In structural biology, DeepMind’s AlphaFold transformed biological workflows by predicting accurate static structures for over 240 million proteins (Sosnick, 2024). In de novo protein design, utilizing structural predictions to filter candidate sequences prior to laboratory synthesis achieves roughly a tenfold increase in experimental success. However, structural prediction represents only a static snapshot. Critical physical properties—such as dynamic conformational ensembles, binding kinetics, side-chain precision at sub-Angstrom scales, and thermodynamic free energy changes—remain unsolved computational frontiers.
III. Materials Discovery and Methodological Bottlenecks
In solid-state materials science, generative frameworks like GNoME have computationally expanded known stable crystal structures by hundreds of thousands. However, critical evaluations in materials chemistry emphasize that predicted structures must meet three strict criteria: credibility, novelty, and utility (Cheetham & Seshadri, 2024). Many computationally stable structures represent minor variations of known lattices rather than functional breakthroughs, and thermodynamic stability does not guarantee laboratory synthesizability or practical application.
Methodologically, machine learning models face deep epistemic limits. Operating as high-dimensional function approximators, they lack explicit mechanistic interpretability, substituting statistical surrogate models for governing physical laws. Additionally, the lack of standardized negative data in scientific literature—where failed experiments and inactive compounds are rarely published—induces systematic optimism during model training, leading algorithms to over-predict candidate viability.
IV. Conclusion
Artificial intelligence has established itself as an indispensable tool for accelerating screening throughput, structural filtering, and multi-property molecular optimization. Yet, machine learning has not replaced the physical scientific method. The core bottlenecks of scientific discovery—understanding complex disease physiology, capturing dynamic molecular mechanics, and engineering functional materials—remain bound to empirical verification. Machines do not independently uncover scientific laws; rather, they serve as powerful instruments of human scientific augmentation
